Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and aims for revenues of C$ 2.0 million or more per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4] Upcoming Financial Results - Microbix is set to file its financial statements and management disclosure for Q1 2025, which ended on December 31, 2024, prior to trading on February 13, 2025 [1] - A webinar discussion regarding the Q1 2025 results will be held at 11:00 AM ET on the same day, featuring the CEO, CFO, and COO [1] Webinar Participation - Investors and shareholders can participate in the webinar by registering through a provided link, and it will also be live-streamed on YouTube [2] - A replay of the webinar will be available on Adelaide Capital's YouTube channel [3] Product and Market Focus - Microbix's antigens are utilized in antibody tests by approximately 100 diagnostics manufacturers, while QAPs are sold to clinical lab accreditation organizations and clinical labs [4] - The company's QAPs are available in over 30 countries, supported by a network of international distributors [4] - Microbix also develops proprietary products such as Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [5]
Microbix Schedules Release of Results for Q1 Fiscal 2025